+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H1 2019

  • ID: 4760838
  • Drug Pipelines
  • March 2019
  • Region: Global
  • 82 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Biogen Inc
  • Daiichi Sankyo Co Ltd
  • EA Pharma Co Ltd
  • Immunwork Inc
  • Morphic Therapeutic Inc
  • MORE
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H1 2019

Summary

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Integrin Alpha 4 is a protein encoded by ITGA4. Integrins alpha-4 (VLA-4) subunit associates with a beta 1 or beta-7 subunit to form an integrin that plays a role in cell motility and migration. This integrin is a therapeutic target for the treatment of multiple sclerosis, Crohn's disease and inflammatory bowel disease. They are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are also receptors for VCAM1.

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) pipeline Target constitutes close to 14 molecules. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 1, 3 and 4 respectively.

Report covers products from therapy areas Gastrointestinal, Central Nervous System, Immunology, Infectious Disease, Oncology, Ophthalmology, Cardiovascular, Genetic Disorders, Respiratory and Undisclosed which include indications Inflammatory Bowel Disease, Ulcerative Colitis, Graft Versus Host Disease (GVHD), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Age Related Macular Degeneration, Asthma, Autoimmune Disorders, Crohn's Disease (Regional Enteritis), Duchenne Muscular Dystrophy, Epilepsy, Genital Warts (Condylomata Acuminata), Human Immunodeficiency Virus (HIV) Infections (AIDS), Keratoconjunctivitis Sicca (Dry Eye), Multiple Sclerosis, Paraneoplastic Syndrome, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Unspecified and Ventricular Septal Defect.

The latest report Integrin Alpha 4 - Pipeline Review, H1 2019, outlays comprehensive information on the Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)
  • The report reviews Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Biogen Inc
  • Daiichi Sankyo Co Ltd
  • EA Pharma Co Ltd
  • Immunwork Inc
  • Morphic Therapeutic Inc
  • MORE
Introduction

Report Coverage

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Overview

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Companies Involved in Therapeutics Development

Antisense Therapeutics Ltd

Biogen Inc

C4X Discovery Holdings PLC

Daiichi Sankyo Co Ltd

EA Pharma Co Ltd

Immunwork Inc

Morphic Therapeutic Inc

Protagonist Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Drug Profiles

AJM-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AS-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATL-1102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AXR-159 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ET-3764 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

natalizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PN-943 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ITGA4 and ITGB7 for Unspecified Indication - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize VLA-4 for Asthma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Integrin Alpha 4 and Beta 2 for Autoimmune Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TE-5232 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vedolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Dormant Products

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Discontinued Products

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Product Development Milestones

Featured News & Press Releases

Mar 11, 2019: Takeda’s Entyvio achieves superior remission than Humira in ulcerative colitis

Mar 11, 2019: Takeda Canada announces positive results for ENTYVIO (vedolizumab) vs. Humira (adalimumab) in first IBD study to compare biological agents head-to-head

Jan 29, 2019: Perrigo To Receive Milestone Payment Of $250 Million From RPI Finance Trust

Jan 18, 2019: Antisense Therapeutics provides phase II clinical trial in duchenne muscular dystrophy

Jan 07, 2019: RM LAW announces class action lawsuit against Perrigo Company

Jan 03, 2019: First Patient enrolled in Biogens phase 3b Study to evaluate Extended Interval Dosing (EID) with Natalizumab in Multiple Sclerosis

Dec 17, 2018: Entyvio post-marketing safety data consistent with previous clinical trials

Dec 13, 2018: Protagonist Therapeutics initiates phase 1 trial of oral, gut-restricted, alpha-4-beta-7 integrin antagonist PN-10943

Nov 27, 2018: Protagonist Therapeutics announces new development candidate PN-10943 for the treatment of inflammatory bowel disease

Nov 07, 2018: Takeda announces launch of Entyvio (vedolizumab) for the treatment of adult patients with moderately to severely active ulcerative colitis in Japan

Oct 27, 2018: Takeda comments on ongoing Phase 1 review by the European Commission of the proposed acquisition of Shire

Oct 22, 2018: Investigational subcutaneous formulation of Vedolizumab achieves and maintains clinical remission and mucosal healing at Week 52 in patients with moderately to severely active Ulcerative Colitis

Oct 11, 2018: Biogen to present on TYSABRI at 34th Congress of the European Committee for Treatment and Research

Oct 08, 2018: New real-world data analyses support the long-term use of Entyvio (Vedolizumab) in bio-naïve patients for the treatment of moderate to severe ulcerative colitis or crohn's disease

Oct 02, 2018: Biogen announces presentation on TYSABRI at ECTRIMS 2018

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Indication, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Pipeline by Antisense Therapeutics Ltd, H1 2019

Pipeline by Biogen Inc, H1 2019

Pipeline by C4X Discovery Holdings PLC, H1 2019

Pipeline by Daiichi Sankyo Co Ltd, H1 2019

Pipeline by EA Pharma Co Ltd, H1 2019

Pipeline by Immunwork Inc, H1 2019

Pipeline by Morphic Therapeutic Inc, H1 2019

Pipeline by Protagonist Therapeutics Inc, H1 2019

Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019

Dormant Products, H1 2019

Dormant Products, H1 2019 (Contd..1), H1 2019

Dormant Products, H1 2019 (Contd..2), H1 2019

Discontinued Products, H1 2019

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Top 10 Indications, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Antisense Therapeutics Ltd
  • Biogen Inc
  • C4X Discovery Holdings PLC
  • Daiichi Sankyo Co Ltd
  • EA Pharma Co Ltd
  • Immunwork Inc
  • Morphic Therapeutic Inc
  • Protagonist Therapeutics Inc
  • Takeda Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll